Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: Results of a North American trial

Journal of Clinical Oncology

Volumn 20, Issue 16, 2002, Pages 3386-3395

  Osborne, C K ^a   Pippen, J ^a   Jones, S E ^a   Parker, L M ^a   Ellis, M ^a   Come, S ^a   Gertler, S Z ^a   May, J T ^a   Burton, G ^a   Dimery, I ^a   Webster, A ^a   Morris, C ^a   Elledge, R ^a   Buzdar, A ^a  

^a HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTIESTROGEN; FULVESTRANT; TAMOXIFEN CITRATE;

ADULT; AGED; ANOREXIA; ARTICLE; ASTHENIA; BACKACHE; BONE PAIN; BREAST CANCER; CANCER GROWTH; CANCER HORMONE THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DYSPNEA; EDEMA; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; NAUSEA; PAIN; PARESTHESIA; PELVIS PAIN SYNDROME; PHARYNGITIS; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; TREATMENT OUTCOME; VASODILATATION; VERTIGO;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; ESTRADIOL; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NITRILES; NORTH AMERICA; POSTMENOPAUSE; QUALITY OF LIFE; SURVIVAL RATE; TRIAZOLES;

EID: 0037102126     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.10.058     Document Type: Article

References (17)

1. Use of tamoxifen for breast cancer: Twenty-eight years later
2. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study
3. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial
4. ICI 182,780 (Faslodex™): Development of a novel, 'pure' antiestrogen
5. A potent specific pure antioestrogen with clinical potential
6. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer
7. Comparison of the short-term biological effects of fulvestrant (ICI 182,780) with tamoxifen in postmenopausal women with primary breast cancer
8. Response to a specific antiestrogen (ICI 182,780) in tamoxifen-resistant breast cancer
9. Pharmacokinetics, pharmacological, and anti-tumour effects of the specific anti-oestrogen ICI 182,780 in women with advanced breast cancer
10. Duration of remission to ICI 182,780 compared to megestrol acetate in tamoxifen resistant breast cancer
11. Fulvestrant, formerly ICI 182, 780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment
12. The Functional Assessment of Cancer Therapy Scale: Development and validation of the general measure
13. Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument
14. Phase II evaluations of LY 156758 in metastatic breast cancer
15. Effects of high dose raloxifene in selected patients with advanced breast carcinoma
16. Multicenter phase II efficacy trial of toremifene in tamoxifen refractory patients with advanced breast cancer
17. High dose toremifene in advanced breast cancer resistant to or relapsed during tamoxifen treatment